AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|
30.4 C
New York
Thursday, September 3, 2026

Tag: tumor

newssourceFORcompanyinformationcontent1releasesmarket

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

        

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Oncorena’s new issue of shares fully subscribed

LUND, Sweden, June 26, 2025 /PRNewswire/ -- Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million...

Oncorena’s new issue of shares fully subscribed

LUND, Sweden, June 26, 2025 /PRNewswire/ -- Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million...

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

Rosalind Franklin University Helix 51 Company UP Oncolytics Secures Wisconsin Economic Development Matching Grant to Advance Oncolytic Virus Therapy for Brain Cancer

NORTH CHICAGO, Ill., June 25, 2025 /PRNewswire/ -- UP Oncolytics, a neuro-oncology biotechnology company based in Milwaukee and a spin-out of the Advocate Aurora Research...

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo.,...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /CNW/ -- Equity Insider News Commentary – Rising rates of cancer...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers